Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine
- Oral treatment danegaptide represents “a potential paradigm shift” toward earlier, non-invasive treatment of Non-Proliferative Diabetic Retinopathy (NPDR), say authors
- Study “provides compelling evidence” that danegaptide robustly protects inner blood-retina barrier (iBRB), while also dampening VEGF-associated activity
- This “dual approach”, and its ability to be used earlier, “may translate into improved outcomes”
- Breye is now planning a Phase II proof-of-concept trial of danegaptide in a targeted NPDR population, due to start in 2027
Copenhagen, Denmark, 23 September 2026 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces that it has had an academic paper on its lead asset danegaptide published in the prestigious journal Science Translational Medicine (STM).
